The novel vaccine peptide GV1001 effectively blocks β-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase

Park, Hyun‐Hee; Lee, Kyu-Yong; Kim, Sangjae; Lee, Jessica Woojin; Choi, Na-Young; Lee, Eun‐Hye; Lee, Young Joo; Lee, Sang-Hun; Koh, Seong‐Ho

doi:10.1016/j.neurobiolaging.2013.12.015

Cited by 59 publications

(41 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on our previous studies, the PI3K/AKT pathway is inhibited by Aβ and its recovery by diverse ways is helpful for the prevention of Aβ toxicity [14,15,54]. This finding is also supported by many other researchers [55][56][57].…”

Section: The Alteration Of the Pi3k/akt Pathway In Adsupporting

confidence: 66%

“…Therefore, GSK-3β inhibition through the activation of PI3K/AKT can be another solution for the treatment of AD. We have reported that GV1001, which is a novel vaccine peptide mimicking Human telomerase reverse transcriptase (hTERT), donepezil, and coenzyme Q10 can block Aβ through the activation of PI3K and AKT and then the inhibition of GSK-3β [14,54,67]. Although the Phase II clinical trial using NP031112, a GSK-3β inhibitor, has not yet shown definite efficacy to AD patients, it showed that its usage was safe.…”

Section: The Therapeutic Possibility Of the Modulation Of The Pi3k/akmentioning

confidence: 99%

See 1 more Smart Citation

The role of PI3K/AKT pathway and its therapeutic possibility in Alzheimer's disease

Koh

2017

Hanyang Med Rev

Self Cite

View full text Add to dashboard Cite

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Alzheimer's disease (AD) is the most common form of dementia. Although uncountable clinical trials have been done to develop the treatment of AD, there are a couple of drugs that can be used only for symptomatic treatment. Therefore, many studies based on the amyloid cascade hypothesis and the tauopathy hypothesis are still ongoing. After the failure of numerous huge Phase III clinical trials, arguments on those hypotheses have arisen and efforts to establish other possible therapeutic strategies based on diverse plausible mechanisms associated with AD have been done as well. One of the new therapeutic targets for AD is the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. In this review, questions on the two hypotheses, the definition of the PI3K/AKT pathway, the relationship between the pathway and AD, and the possibility of the modulation of the pathway as a new therapeutic strategy for AD will be discussed briefly.

show abstract

Section: The Alteration Of the Pi3k/akt Pathway In Adsupporting

confidence: 66%

Section: The Therapeutic Possibility Of the Modulation Of The Pi3k/akmentioning

confidence: 99%

The role of PI3K/AKT pathway and its therapeutic possibility in Alzheimer's disease

Koh

2017

Hanyang Med Rev

Self Cite

View full text Add to dashboard Cite

show abstract

“…Also, a HA‐tagged hTERT that could not elongate telomeres was found to protect against apoptosis [54]. Lastly, a 16 amino acid sequence of the catalytically active site of hTERT, GV1001, was found to be sufficient to confer extra‐telomeric functions, in the absence of canonical telomerase activity in cells [55].…”

Section: Discussionmentioning

confidence: 99%

Quantitative assessment of telomerase components in cancer cell lines

et al. 2015

View full text Add to dashboard Cite

a b s t r a c tBesides its canonical function of catalyzing the formation of telomeric repeats, many groups have recently reported non-canonical functions of hTERT in particular, and telomerase in general. Regulating transcription is the central basis of non-canonical functions of telomerase. However, unlike reverse transcriptase activity of telomerase that requires only a few molecules of enzymatically active hTERT, non-canonical functions of hTERT or other telomerase components theoretically require several hundred copies. Here, we provide the first direct quantification of all the telomerase components in human cancer cell lines. We demonstrate that telomerase components do not exist in a 1:1 stoichiometric ratio, and there are several hundred copies of hTERT in cells. This provides the molecular basis of hTERT to function in other signaling cascades, including transcription.

show abstract

“…Excellent papers on A␤ vaccines from universities were presented (in chronological order): 2012: non-human random sequence amyloid oligomer mimic [622], a new gene vaccine encoding ten repeats of A␤ 3-10 [623], active DNA Abeta42 vaccination [624], short A␤ immunogens [625], mutated A␤ sensitized dendritic cells [626], preventive immunization [627] 2013: immunotherapeutic efficiency of a tetravalent A␤ 1-15 vaccine [628], recombinant DNA vaccine [629], multivalent A␤3-10 DNA vaccine [630], a peptide prime-DNA boost immunization [631], a new DNA vaccine YM-3711 [632], an effective DNA epitope chimeric vaccine [633], 2014: vaccination, which induced changes in pro-inflammatory cytokine levels and lead to cognitive improvement [634] and recombinant chimeric vaccines [635]. The novel vaccine peptide GV1001 effectively blocked A␤ toxicity [636]. Excellent reviews on A␤ vaccines have been provided (in chronological order) 2012: [637], 2013: [638,639], 2014: [640,641].…”

Section: Rgd-ditox [382-401]-kk-abeta [1-13]mentioning

confidence: 99%

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-Modifying Drugs. Update 2014

Froestl

Pfeifer

Muhs

2014

JAD

View full text Add to dashboard Cite

Scientists working in the field of Alzheimer's disease and, in particular, cognitive enhancers, are very productive. The review "Drugs interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs" was accepted in October 2012. In the last 20 months, new targets for the potential treatment of Alzheimer's disease were identified. Enormous progress was realized in the pharmacological characterization of natural products with cognitive enhancing properties. This review covers the evolution of research in this field through May 2014.

show abstract

The novel vaccine peptide GV1001 effectively blocks β-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase

Cited by 59 publications

References 45 publications

The role of PI3K/AKT pathway and its therapeutic possibility in Alzheimer's disease

The role of PI3K/AKT pathway and its therapeutic possibility in Alzheimer's disease

Quantitative assessment of telomerase components in cancer cell lines

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-Modifying Drugs. Update 2014

Contact Info

Product

Resources

About